TRVI vs. LFCR, GALT, ACRV, RIGL, OMER, GBIO, OVID, ATOS, RENB, and MACK
Should you be buying Trevi Therapeutics stock or one of its competitors? The main competitors of Trevi Therapeutics include Lifecore Biomedical (LFCR), Galectin Therapeutics (GALT), Acrivon Therapeutics (ACRV), Rigel Pharmaceuticals (RIGL), Omeros (OMER), Generation Bio (GBIO), Ovid Therapeutics (OVID), Atossa Therapeutics (ATOS), Renovaro (RENB), and Merrimack Pharmaceuticals (MACK). These companies are all part of the "pharmaceutical preparations" industry.
Trevi Therapeutics (NASDAQ:TRVI) and Lifecore Biomedical (NASDAQ:LFCR) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their community ranking, valuation, analyst recommendations, media sentiment, earnings, risk, dividends, profitability and institutional ownership.
Trevi Therapeutics received 77 more outperform votes than Lifecore Biomedical when rated by MarketBeat users. Likewise, 60.94% of users gave Trevi Therapeutics an outperform vote while only 12.50% of users gave Lifecore Biomedical an outperform vote.
Trevi Therapeutics has higher earnings, but lower revenue than Lifecore Biomedical. Trevi Therapeutics is trading at a lower price-to-earnings ratio than Lifecore Biomedical, indicating that it is currently the more affordable of the two stocks.
Trevi Therapeutics has a beta of 0.91, indicating that its stock price is 9% less volatile than the S&P 500. Comparatively, Lifecore Biomedical has a beta of 0.98, indicating that its stock price is 2% less volatile than the S&P 500.
In the previous week, Trevi Therapeutics had 11 more articles in the media than Lifecore Biomedical. MarketBeat recorded 16 mentions for Trevi Therapeutics and 5 mentions for Lifecore Biomedical. Lifecore Biomedical's average media sentiment score of 0.47 beat Trevi Therapeutics' score of 0.18 indicating that Lifecore Biomedical is being referred to more favorably in the news media.
Trevi Therapeutics currently has a consensus target price of $8.50, suggesting a potential upside of 207.41%. Lifecore Biomedical has a consensus target price of $9.50, suggesting a potential upside of 58.60%. Given Trevi Therapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe Trevi Therapeutics is more favorable than Lifecore Biomedical.
95.8% of Trevi Therapeutics shares are held by institutional investors. Comparatively, 83.4% of Lifecore Biomedical shares are held by institutional investors. 27.5% of Trevi Therapeutics shares are held by insiders. Comparatively, 14.6% of Lifecore Biomedical shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Lifecore Biomedical's return on equity of 0.00% beat Trevi Therapeutics' return on equity.
Summary
Trevi Therapeutics beats Lifecore Biomedical on 10 of the 16 factors compared between the two stocks.
Get Trevi Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for TRVI and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding TRVI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Trevi Therapeutics Competitors List
Related Companies and Tools
